FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019927335> ?p ?o ?g. }

• W2019927335 endingPage "55" @default.
• W2019927335 startingPage "45" @default.
• W2019927335 abstract "Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Adhesion molecules play important roles in cell–cell and cell–extracellular matrix (ECM) interactions in inflammation. Blocking the interaction between inflammatory cells and vascular endothelia can prevent cell entry into tissues and harmful inflammatory responses, that is, autoimmunity, but could also limit immunosurveillance by anti‐viral T cells in sites of infection or latency. Development of progressive multifocal leukoencephalopathy in patients treated with antibody against very late antigen (VLA)‐4 prompted us to explore an alternative therapeutic approach. We used an antibody against the integrin α2, VLA‐2, that interacts with ECM, not vascular endothelium. SJL/J mice were sensitized with myelin proteolipid protein (PLP) 139–151 peptide to induce experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Treatment of mice with VLA‐2 antibody suppressed clinical signs and CNS inflammation of EAE, when antibody was given immediately after disease onset. In contrast, VLA‐4 or VLA‐2 antibody treatment of mice during the priming or remission phase of EAE had minor effects on the disease’s clinical course. No differences were found in lymphoproliferative responses to PLP 139–151 among treatment groups. Data suggest that blocking cell–ECM interactions can be an alternative therapy for MS." @default.
• W2019927335 created "2016-06-24" @default.
• W2019927335 creator A5001924858 @default.
• W2019927335 creator A5005409328 @default.
• W2019927335 creator A5029994349 @default.
• W2019927335 creator A5051928962 @default.
• W2019927335 creator A5053882982 @default.
• W2019927335 creator A5074673340 @default.
• W2019927335 date "2007-01-01" @default.
• W2019927335 modified "2023-10-16" @default.
• W2019927335 title "Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade" @default.
• W2019927335 cites W139189782 @default.
• W2019927335 cites W1483896637 @default.
• W2019927335 cites W1502615517 @default.
• W2019927335 cites W1514064771 @default.
• W2019927335 cites W1514090240 @default.
• W2019927335 cites W1523195645 @default.
• W2019927335 cites W1524870232 @default.
• W2019927335 cites W1531027674 @default.
• W2019927335 cites W1576773659 @default.
• W2019927335 cites W1587801474 @default.
• W2019927335 cites W1605861898 @default.
• W2019927335 cites W1610027395 @default.
• W2019927335 cites W1631432577 @default.
• W2019927335 cites W1964186579 @default.
• W2019927335 cites W1964421053 @default.
• W2019927335 cites W1967415789 @default.
• W2019927335 cites W1970547229 @default.
• W2019927335 cites W1975231279 @default.
• W2019927335 cites W1980590617 @default.
• W2019927335 cites W1982947309 @default.
• W2019927335 cites W1986160938 @default.
• W2019927335 cites W1987514824 @default.
• W2019927335 cites W1989737574 @default.
• W2019927335 cites W1993653872 @default.
• W2019927335 cites W1998576498 @default.
• W2019927335 cites W1999702140 @default.
• W2019927335 cites W2000379621 @default.
• W2019927335 cites W2001129679 @default.
• W2019927335 cites W2007469704 @default.
• W2019927335 cites W2011723257 @default.
• W2019927335 cites W2014069023 @default.
• W2019927335 cites W2014954180 @default.
• W2019927335 cites W2015780294 @default.
• W2019927335 cites W2018456133 @default.
• W2019927335 cites W2020142113 @default.
• W2019927335 cites W2021747720 @default.
• W2019927335 cites W2025834550 @default.
• W2019927335 cites W2027627443 @default.
• W2019927335 cites W2028061046 @default.
• W2019927335 cites W2035147260 @default.
• W2019927335 cites W2040632916 @default.
• W2019927335 cites W2046369009 @default.
• W2019927335 cites W2055986945 @default.
• W2019927335 cites W205599027 @default.
• W2019927335 cites W2057627593 @default.
• W2019927335 cites W2059114092 @default.
• W2019927335 cites W2059313909 @default.
• W2019927335 cites W2063419701 @default.
• W2019927335 cites W2064384823 @default.
• W2019927335 cites W2074353579 @default.
• W2019927335 cites W2076343582 @default.
• W2019927335 cites W2077944387 @default.
• W2019927335 cites W2078430285 @default.
• W2019927335 cites W2079650747 @default.
• W2019927335 cites W2083078071 @default.
• W2019927335 cites W2084916103 @default.
• W2019927335 cites W2089274399 @default.
• W2019927335 cites W2095390622 @default.
• W2019927335 cites W2097021075 @default.
• W2019927335 cites W2097438831 @default.
• W2019927335 cites W2097765596 @default.
• W2019927335 cites W2098727982 @default.
• W2019927335 cites W2101958789 @default.
• W2019927335 cites W2106467284 @default.
• W2019927335 cites W2107012136 @default.
• W2019927335 cites W2107646063 @default.
• W2019927335 cites W2108617074 @default.
• W2019927335 cites W2123713559 @default.
• W2019927335 cites W2124376257 @default.
• W2019927335 cites W2128255470 @default.
• W2019927335 cites W2135121318 @default.
• W2019927335 cites W2137495383 @default.
• W2019927335 cites W2138223843 @default.
• W2019927335 cites W2141924291 @default.
• W2019927335 cites W2144912209 @default.
• W2019927335 cites W2148338297 @default.
• W2019927335 cites W2155149710 @default.
• W2019927335 cites W2161681716 @default.
• W2019927335 cites W2169726349 @default.
• W2019927335 cites W4239143981 @default.
• W2019927335 doi "https://doi.org/10.1111/j.1750-3639.2006.00042.x" @default.
• W2019927335 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8095550" @default.
• W2019927335 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17493037" @default.
• W2019927335 hasPublicationYear "2007" @default.
• W2019927335 type Work @default.
• W2019927335 sameAs 2019927335 @default.
• W2019927335 citedByCount "31" @default.

• next